Paolo Magni (P Magni)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 34

Top Venues

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

Pharmaceutics

ACS synthetic biology

Università degli Studi di Pavia

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Università degli Studi di Pavia

Italy

Professor :: Electrical, Computer and Biomedical Engineering

Publications

Davide De Marchi, Roman Shaposhnikov, Samy Gobaa, Daniele Pastorelli, Gregory Batt, Paolo Magni, Lorenzo Pasotti
Design and Model-Driven Analysis of Synthetic Circuits with the Staphylococcus aureus Dead-Cas9 (sadCas9) as a Programmable Transcriptional Regulator in Bacteria. ACS synthetic biology 13 (3) (2024)
Elena M Tosca, Alessandro De Carlo, Roberta Bartolucci, Francesco Fiorentini, Silvia Di Tollo, Maurizio Caserini, Maurizio Rocchetti, Paolo Bettica, Paolo Magni
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Alessandro De Carlo, Davide Ronchi, Marco Piastra, Elena Maria Tosca, Paolo Magni
Predicting ADMET Properties from Molecule SMILE: A Bottom-Up Approach Using Attention-Based Graph Neural Networks. Pharmaceutics 16 (6) (2024)
Elena Maria Tosca, Alessandro De Carlo, Davide Ronchi, Paolo Magni
Model-Informed Reinforcement Learning for Enabling Precision Dosing Via Adaptive Dosing. Clinical pharmacology and therapeutics (2024)
Davide De Marchi, Roman Shaposhnikov, Samy Gobaa, Daniele Pastorelli, Gregory Batt, Paolo Magni, Lorenzo Pasotti
Design and Model-Driven Analysis of Synthetic Circuits with the Staphylococcus aureus Dead-Cas9 (sadCas9) as a Programmable Transcriptional Regulator in Bacteria. ACS synthetic biology 13 (3) (2024)
Alessandro De Carlo, Elena Maria Tosca, Martina Fantozzi, Paolo Magni
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma. Clinical pharmacology and therapeutics 115 (4) (2024)
Elena Maria Tosca, Alessandro De Carlo, Davide Ronchi, Paolo Magni
Model-Informed Reinforcement Learning for Enabling Precision Dosing Via Adaptive Dosing. Clinical pharmacology and therapeutics 116 (3) (2024)
Davide De Marchi, Roman Shaposhnikov, Samy Gobaa, Daniele Pastorelli, Gregory Batt, Paolo Magni, Lorenzo Pasotti
Design and Model-Driven Analysis of Synthetic Circuits with the Staphylococcus aureus Dead-Cas9 (sadCas9) as a Programmable Transcriptional Regulator in Bacteria. ACS synthetic biology (2024)
Alessandro De Carlo, Elena Maria Tosca, Martina Fantozzi, Paolo Magni
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma. Clinical pharmacology and therapeutics (2024)
Elena M Tosca, Alessandro De Carlo, Roberta Bartolucci, Francesco Fiorentini, Silvia Di Tollo, Maurizio Caserini, Maurizio Rocchetti, Paolo Bettica, Paolo Magni
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Alessandro De Carlo, Davide Ronchi, Marco Piastra, Elena Maria Tosca, Paolo Magni
Predicting ADMET Properties from Molecule SMILE: A Bottom-Up Approach Using Attention-Based Graph Neural Networks. Pharmaceutics 16 (6) (2024)
Elena M Tosca, Alessandro De Carlo, Roberta Bartolucci, Francesco Fiorentini, Silvia Di Tollo, Maurizio Caserini, Maurizio Rocchetti, Paolo Bettica, Paolo Magni
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Alessandro De Carlo, Elena Maria Tosca, Martina Fantozzi, Paolo Magni
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma. Clinical pharmacology and therapeutics 115 (4) (2024)
Elena M Tosca, Alessandro De Carlo, Roberta Bartolucci, Francesco Fiorentini, Silvia Di Tollo, Maurizio Caserini, Maurizio Rocchetti, Paolo Bettica, Paolo Magni
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Elena M Tosca, Alessandro De Carlo, Roberta Bartolucci, Francesco Fiorentini, Silvia Di Tollo, Maurizio Caserini, Maurizio Rocchetti, Paolo Bettica, Paolo Magni
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients. CPT: pharmacometrics & systems pharmacology (2024)
Davide De Marchi, Roman Shaposhnikov, Samy Gobaa, Daniele Pastorelli, Gregory Batt, Paolo Magni, Lorenzo Pasotti
Design and Model-Driven Analysis of Synthetic Circuits with the Staphylococcus aureus Dead-Cas9 (sadCas9) as a Programmable Transcriptional Regulator in Bacteria. ACS synthetic biology 13 (3) (2024)
Alessandro De Carlo, Elena Maria Tosca, Martina Fantozzi, Paolo Magni
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma. Clinical pharmacology and therapeutics 115 (4) (2024)
Elena Maria Tosca, D Ronchi, M Rocchetti, Paolo Magni
Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach. The AAPS journal 26 (5) (2024)
Elena M Tosca, Alessandro De Carlo, Roberta Bartolucci, Francesco Fiorentini, Silvia Di Tollo, Maurizio Caserini, Maurizio Rocchetti, Paolo Bettica, Paolo Magni
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Elena M Tosca, Alessandro De Carlo, Roberta Bartolucci, Francesco Fiorentini, Silvia Di Tollo, Maurizio Caserini, Maurizio Rocchetti, Paolo Bettica, Paolo Magni
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Elena Maria Tosca, Davide Ronchi, Daniele Facciolo, Paolo Magni
Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment. Biomedicines 11 (4) (2023)
Alessandro De Carlo, Elena Maria Tosca, Nicola Melillo, Paolo Magni
A two-stages global sensitivity analysis by using the δ sensitivity index in presence of correlated inputs: application on a tumor growth inhibition model based on the dynamic energy budget theory. Journal of pharmacokinetics and pharmacodynamics (2023)
Elena M Tosca, Elisa Borella, Chiara Piana, Salim Bouchene, Giuseppe Merlino, Alessio Fiascarelli, Paolo Mazzei, Paolo Magni
Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients. CPT: pharmacometrics & systems pharmacology (2023)
Sarah L Stenton, Melanie O'Leary, Gabrielle T Lemire, Grace E VanNoy, Stephanie DiTroia, Vijay S Ganesh, Emily Groopman, Emily O'Heir, Brian Mangilog, Ikeoluwa Osei-Owusu, Lynn S Pais, Jillian G Serrano, Moriel H Singer-Berk, Ben Weisburd, Michael Wilson, Christina Austin-Tse, Marwa Abdelhakim, Azza Thamer Althagafi, Giulia Babbi, Riccardo Bellazzi, Samuele Bovo, Maria Giulia Carta, Rita Casadio, Pieter-Jan Coenen, Federica De Paoli, Matteo Floris, Manavalan Gajapathy, Hoehndorf Robert, Julius O B Jacobsen, Thomas Joseph, Akash Kamandula, Panagiostis Katsonis, Cyrielle Kint, Olivier Lichtarge, Ivan Limongelli, Yulan Lu, Paolo Magni, Tarun Karthik Kumar Mamidi, Pier Luigi Martelli, Marta Mulargia, Giovanna Nicora, Keith Nykamp, Vikas Pejaver, Yisu Peng, Thi Hong Cam Pham, Maurizio S Podda, Aditya Rao, Ettore Rizzo, Vangala G Saipradeep, Castrense Savojardo, Peter Schols, Yang Shen, Naveen Sivadasan, Damian Smedley, Dorian Soru, Rajgopal Srinivasan, Yuanfei Sun, Uma Sunderam, Wuwei Tan, Naina Tiwari, Xiao Wang, Yaqiong Wang, Amanda Williams, Elizabeth A Worthey, Rujie Yin, Yuning You, Daniel Zeiberg, Susanna Zucca, Constantina Bakolitsa, Steven E Brenner, Stephanie Malia Fullerton, Predrag Radivojac, Michael J Bamshad, Anne H O'Donnell-Luria
Critical assessment of variant prioritization methods for rare disease diagnosis within the Rare Genomes Project. medRxiv : the preprint server for health sciences (2023)
Elena Maria Tosca, Davide Ronchi, Daniele Facciolo, Paolo Magni
Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment. Biomedicines 11 (4) (2023)
Elena Maria Tosca, Maurizio Rocchetti, Elena Pérez, Conchi Nieto, Paolo Bettica, Jaime Moscoso Del Prado, Paolo Magni, Giuseppe De Nicolao
In Vitro-In Vivo Correlation (IVIVC) Population Modeling for the In Silico Bioequivalence of a Long-Acting Release Formulation of Progesterone. Pharmaceutics 13 (2) (2021)
Elena Maria Tosca, Roberta Bartolucci, Paolo Magni
Application of Artificial Neural Networks to Predict the Intrinsic Solubility of Drug-Like Molecules. Pharmaceutics 13 (7) (2021)
Maria Garcia-Cremades, Nicola Melillo, Iñaki F Trocóniz, Paolo Magni
Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer. Clinical and translational science 13 (3) (2020)
Nicola Melillo, Silvia Grandoni, Nicola Cesari, Giandomenico Brogin, Paola Puccini, Paolo Magni
Inter-compound and Intra-compound Global Sensitivity Analysis of a Physiological Model for Pulmonary Absorption of Inhaled Compounds. The AAPS journal 22 (5) (2020)
Elisa Borella, Italo Poggesi, Paolo Magni
Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs. Clinical pharmacokinetics 57 (4) (2019)
E M Tosca, M C Pigatto, T Dalla Costa, Paolo Magni
A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats. Pharmaceutical research 36 (3) (2019)
Lorenzo Pasotti, Massimo Bellato, Michela Casanova, Susanna Zucca, Maria Gabriella Cusella De Angelis, Paolo Magni
Re-using biological devices: a model-aided analysis of interconnected transcriptional cascades designed from the bottom-up. Journal of biological engineering 11 (2017)
Lorenzo Pasotti, Susanna Zucca, Michela Casanova, Giuseppina Micoli, Maria Gabriella Cusella De Angelis, Paolo Magni
Fermentation of lactose to ethanol in cheese whey permeate and concentrated permeate by engineered Escherichia coli. BMC biotechnology 17 (1) (2017)
Michela Casanova, Lorenzo Pasotti, Susanna Zucca, Nicolò Politi, Ilaria Massaiu, Cinzia Calvio, Maria Gabriella Cusella De Angelis, Paolo Magni
A BioBrick™-Compatible Vector for Allelic Replacement Using the XylE Gene as Selection Marker. Biological procedures online 18 (2016)
Alessandra Tiengo, Lorenzo Pasotti, Nicola Barbarini, Paolo Magni
PhosphoHunter: An Efficient Software Tool for Phosphopeptide Identification. Advances in bioinformatics 2015 (2015)

Paolo Magni.css-eqlu8i{font-size:small;padding-left:4px;} (P Magni)

Publication Activity (10 Years)

Top Topics

Top Venues

Paolo Magni (P Magni)